Spiolto Respimat (Tiotropium and Olodaterol) – COPD | DengYue Medicine

Spiolto Respimat Application Scope

Spiolto Respimat is a prescription inhaler combining tiotropium and olodaterol, used once daily to manage chronic obstructive pulmonary disease (COPD) by improving airflow and reducing symptoms like shortness of breath.

Characteristics

• Ingredients: Tiotropium and Olodaterol

• Properties:

  • Combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic agonist (LABA)

  • Provides bronchodilation for improved airflow in COPD patients

  • Not indicated for asthma treatment or acute COPD exacerbations

• Packaging Specification:

  Inhalation spray available in:

  • 60 metered actuations (standard pack)

  • 10 metered actuations (institutional pack)

• Storage:

  • Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)

  • Avoid freezing

  • Keep out of reach of children

• Expiry Date:

  • Discard 3 months after first use, when the inhaler locks.

  • When the dose indicator reaches zero, whichever comes first.

• Executive Standard: Complies with regulatory standards as approved by relevant health authorities

• Approval Number: Specific approval numbers vary by country and regulatory body

• Date of Revision: January 2025

• Manufacturer: Boehringer Ingelheim

Guidelines for the Use of Spiolto Respimat

• Dosage and Administration:

  • Two inhalations once daily at the same time each day

  • For oral inhalation only

  • No dosage adjustment required for geriatric, hepatic, or renal impairment.

  • However, monitor patients with moderate to severe renal impairment for anticholinergic effects

• Adverse Reactions:

  • Common (>3% incidence):

    • • Nasopharyngitis

      • Cough

      • Back pain

  • Other reported effects:

    • • Dizziness

      • Headache

      • Tachycardia

      • Dry mouth

• Contraindications:

  • Hypersensitivity to tiotropium, olodaterol, atropine, or its derivatives (e.g., ipratropium or oxitropium)

  • Use in asthma patients without an inhaled corticosteroid

• Precautions:

  Use with caution when co-administered with:

  • Other adrenergic agents

  • Xanthine derivatives

  • Steroids

  • Diuretics (especially non-potassium sparing)

  • Monoamine oxidase inhibitors (MAOIs)

  • Tricyclic antidepressants (TCAs)

  • Beta-blockers

  • Other anticholinergic-containing drugs

Spiolto Respimat Interactions

• Drug Interactions:

  • Potential interactions with strong CYP3A4 inducers/inhibitors (may alter Alfosbuvir metabolism)

  • No significant interactions reported with Daclatasvir in clinical studies

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.